Zura Bio Limited, a clinical-stage immunology company, has announced the launch of TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS). This study is the first to assess the dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in this patient population. The 28-week study will include a 16-week primary efficacy assessment and a 12-week safety follow-up, with an optional open-label extension. Approximately 180 participants will be enrolled across clinical sites in the United States, Canada, and Europe. Topline results for the primary efficacy endpoint are anticipated in the third quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250520429104) on May 20, 2025, and is solely responsible for the information contained therein.